ArticleJournal of the Egyptian National Cancer Institute2026
Global burden of multiple myeloma(1990-2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveMultiple myeloma (MM), being the second-most frequently occurring hematologic malignancy, is comprehensively assessed for its global disease burden and risk factors using the Global Burden of Disease (GBD) database and Mendelian Randomization (MR).
methodsThis research utilized data from the GBD 2021 database to extensively investigate age-standardized incidence rates, mortality rates, as well as Disability - Adjusted Life Years (DALYs) linked to MM. We evaluated the impact of various geographical areas, age brackets, genders, risk factors, and Socio-Demographic Index (SDI) on the disease burden of MM. Additionally, Joinpoint regression was employed by us to analyze the temporal trends of this burden. We integrated GBD data with a two-sample MR method for causal inference to further investigate causal relationships between risk factors and MM. Finally, we applied Bayesian-Age-Period-Cohort (BAPC) models to predict future trends in MM's disease burden by using GBD data as a foundation.
resultsIn 2021, the global incidence of MM was 148,755 cases, with 116,359 deaths and a total of 2,595,595 DALYs. The global age-standardized rates of MM were 1.74 (incidence), 1.37 (mortality), and 30.00 (DALYs) per 100,000 population, with higher rates observed in high-income areas. From 1990 to 2021, the annual average percentage change (AAPC) in global MM incidence was 0.54%, mortality was 0.20%, and DALYs was 0.18%. The MM burden associated with high BMI was concentrated within high-income areas such as those in Australasia and North America, while South Asia and Southeast Asia exhibited the lowest proportional burden. To further validate the causal link between BMI and MM, we conducted a two-sample MR.
conclusionOver 30 years, the worldwide burden of MM has shown a significant rise. High-income countries show slowing trends due to improved healthcare, while low/middle-income regions face rising burdens from underdiagnosis and limited access. We demonstrate a positive association between elevated BMI and increased MM risk by using MR, underscoring the imperative for obesity control in high-income nations to alleviate the MM disease burden. This study offers a basis for optimizing global health policies, improving early diagnosis, and resource allocation against the ongoing threat of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.